News

The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major

Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or

The Company also announced three new vaccine development candidates, which support the Company’s strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines

This eight-week trial randomized 402 adult patients equally at more than 45 centers in the United States. In this trial, troriluzole monotherapy at 100mg twice daily did not differentiate

The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous

The late-stage trial called PANORAMA, which features 402 patients, has been assessing Eylea in comparison to sham injection for the improvement of moderately severe to severe NPDR without

In the study, 144 participants were randomized to receive either the vaccine or placebo to prevent recurrence. The vaccines were initiated within three months of completion of standard

The transaction contemplates the retention of nearly the entirety of the Valeritas workforce. To accomplish the sale in the most efficient manner, Valeritas and its subsidiaries filed voluntary

The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known